Overactive Bladder clinical trials at University of California Health
11 research studies open to eligible people
Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
open to eligible people ages 18 years and up
The goal of this prospective, multicenter, single-arm study is to test the safety and effectiveness of eCoin ® tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The main questions it aims to answer are: - The proportion of subjects achieving at least a 50% improvement in the number of urgency urinary incontinence episodes on a 3-day voiding diary (72 hours) after 12 months of therapy. - The rate of device- or procedure-related AEs through 12 months post-activation of eCoin ®. Participants will be implanted with eCoin ® and complete voiding diaries and patient reported-outcomes through 12 months of eCoin ® therapy.
at UC Irvine
Oxybutynin for Post-surgical Bladder Pain and Urgency
open to eligible people ages 4-8
Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.
at UC Davis
BlueWind RENOVA iStim™ System for the Treatment of OAB
open to eligible females ages 18-80
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
at UC Irvine
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
open to eligible people ages 18 years and up
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
at UC Irvine
TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms
open to eligible people ages 18 years and up
To evaluate the safety and effectiveness of the TheraNova Neuromodulation System in overactive bladder (OAB) patients. The primary safety endpoint will be device-related adverse events. The primary effectiveness endpoint will be urinary urge incontinence (UUI) responder rate at 12 weeks (a responder is defined as a subject who experiences at least a 50% reduction in the mean frequency of UUI events per day from baseline to 12 weeks as measured in the 3-day voiding diaries). Responder rate will be compared between subjects randomized to the active treatment vs. the sham treatment.
at UC Davis
TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
open to eligible people ages 18 years and up
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
at UC Davis
INTIBIA Pivotal Study
open to eligible people ages 22-80
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
at UCLA
Intradetrusor Botulinum Toxin A: Are Less Injections Better?
open to eligible females ages 18 years and up
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.
at UC Irvine
TEST-ON - Does iStim Reduce Urinary Urgency?
open to eligible females ages 18-120
Overactive bladder (OAB) is a chronic disorder with an overall prevalence in the adult population of over 10%, but that may exceed 40% in elderly groups. Most overactive bladder treatments are aimed at decreasing urgency incontinence episodes. The purpose of this study is to determine whether an at-home transvaginal electrical stimulation (TES) program works to alleviate symptoms of urgency in patients with urinary urgency and frequency without incontinence. This is a cross-over trial. Women >18 yo presenting with OAB-dry will be randomized to receive one of two TES at home programs for 4 weeks. After completion of the program, the participant's symptoms will be assessed with standardized patient questionnaires. There will then be a 3 week washout period followed by the second at-home TES program. At the completion of the second program, the participant's symptoms will be assessed with the same standardized questionnaires. The participants will be followed for 6 months following the completion of the TES program.
at UCLA
TReating Incontinence for Underlying Mental and Physical Health
open to eligible females ages 60 years and up
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.
at UCSF
Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study
open to eligible females ages 18-80
The goal is to investigate the feasibility and effects of adding "wearables for the bladder" devices to conventional pelvic floor physical therapy (PFPT) to bladder function, in people with multiple sclerosis (MS).
at UCSF
Our lead scientists for Overactive Bladder research studies include Valerie J Block, DPTSc Dena Moskowitz, MD Elaine Waetjen, MD Alison Huang Eric A Kurzrock, MD Felicia Lane, MD Victor Nitti, MD.
Last updated: